Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Y Ohe

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2005
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancerY Ohe, S Negoro, K Matsui, et al.
Japanese Journal of Clinical Oncology|June 6, 1998
Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology GroupT Kasai, Y Ohe, K Nishio, et al.
The Thoracic and Cardiovascular Surgeon|October 23, 2003
Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancerK Hotta, I Sekine, K Suzuki, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLCY Uehara, Y Takeyasu, T Yoshida, et al.
Japanese Journal of Clinical Oncology|March 18, 2000
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancerY Hosomi, Y Ohe, K Mito, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancerH Kunitoh, Y Akiyama, H Kusaba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patientsY Ohe, S Niho, R Kakinuma, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Japanese Journal of Clinical Oncology|November 7, 2001
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601)S Tsuchiya, Y Ohe, T Sugiura, et al.
Die Pharmazie|June 3, 2021
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analysesT Arami, H Kawazoe, R Uozumi, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2005
Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancerY Ohe, S Negoro, K Matsui, et al.
Japanese Journal of Clinical Oncology|June 6, 1998
Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology GroupT Kasai, Y Ohe, K Nishio, et al.
The Thoracic and Cardiovascular Surgeon|October 23, 2003
Distant failure after treatment of postoperative locoregional recurrence of non-small cell lung cancerK Hotta, I Sekine, K Suzuki, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLCY Uehara, Y Takeyasu, T Yoshida, et al.
Japanese Journal of Clinical Oncology|March 18, 2000
Phase I study of cisplatin and docetaxel plus mitomycin C in patients with metastatic non-small cell lung cancerY Hosomi, Y Ohe, K Mito, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2001
A phase I/II trial of cisplatin, docetaxel and ifosfamide in advanced or recurrent non-small cell lung cancerH Kunitoh, Y Akiyama, H Kusaba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 18, 2003
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patientsY Ohe, S Niho, R Kakinuma, et al.
Lung Cancer (Amsterdam, Netherlands)|January 8, 2004
Consensus: the follow-up of the treated patientM Saunders, J P Sculier, D Ball, et al.
Japanese Journal of Clinical Oncology|November 7, 2001
Randomized phase I study of standard-fractionated or accelerated-hyperfractionated radiotherapy with concurrent cisplatin and vindesine for unresectable non-small cell lung cancer: a report of Japan Clinical Oncology Group Study (JCOG 9601)S Tsuchiya, Y Ohe, T Sugiura, et al.
Die Pharmazie|June 3, 2021
Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: a multicenter retrospective study using three propensity score analysesT Arami, H Kawazoe, R Uozumi, et al.
Pageof 20